Splenic stimulation study for active rheumatoid arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study tests a treatment that stimulates the spleen to help calm symptoms of active rheumatoid arthritis (RA). It’s mainly for people whose RA has not improved enough after several newer arthritis medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have rheumatoid arthritis for at least 6 months (based on standard RA diagnosis rules).
- You’re age 22 to 75 and currently have active (ongoing) RA symptoms.
- Your RA has not responded well to at least 2 biologic medicines and/or JAK inhibitors, including one TNF inhibitor.
- You either are taking standard-dose conventional RA medicines now, or you’ve stopped them in the past because they didn’t work or caused side effects.
- You can safely have screening tests done and sign informed consent.
- You haven’t had your spleen removed (no splenectomy) and don’t have a history of vagotomy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether splenic stimulation (using a medical device to stimulate the spleen) is safe for people with active rheumatoid arthritis. It may help some patients who have not improved enough after at least two other advanced arthritis medicines.
This trial tests whether ultrasound waves applied to the spleen can reduce inflammation in adults with rheumatoid arthritis. It is for people with moderate to severe disease who have not tried many biologic medications.
This study tests a new medication called AZD1163 for people with rheumatoid arthritis (RA) that hasn't responded well enough to standard treatments. It aims to see if the drug can safely reduce joint swelling and pain.
This study tests a new oral medication, PTC844, for people with active rheumatoid arthritis whose current treatments have not worked well enough or who haven't tried any yet. The goal is to see if it can reduce joint pain and swelling.
This trial tests sarilumab, an injected antibody that blocks a key protein involved in inflammation, for people with moderate-to-severe rheumatoid arthritis (RA) who haven't had success with standard treatments. The goal is to see if adding sarilumab can help control joint pain and swelling.
This Phase 4 study tests whether a JAK inhibitor (baricitinib) can improve how RA-related bone erosion heals. You might be eligible if you have rheumatoid arthritis that is still active despite methotrexate treatment, and you meet the specific safety and medication history rules.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.